CAGE Bio Announces Positive Clinical Phase 2 Study Results for Atopic Dermatitis

  • Home
  • About Us
    • Board of Directors
    • Scientific Advisory Board
    • Business Advisors
    • Partnerships
  • Our Technology
  • People
    • Our Team
    • Career
  • Patients
    • Clinical Trials
  • Media
    • Press Releases
    • In the news
    • Publications
  • Contact Us
  • More
    • Home
    • About Us
      • Board of Directors
      • Scientific Advisory Board
      • Business Advisors
      • Partnerships
    • Our Technology
    • People
      • Our Team
      • Career
    • Patients
      • Clinical Trials
    • Media
      • Press Releases
      • In the news
      • Publications
    • Contact Us
  • Home
  • About Us
    • Board of Directors
    • Scientific Advisory Board
    • Business Advisors
    • Partnerships
  • Our Technology
  • People
    • Our Team
    • Career
  • Patients
    • Clinical Trials
  • Media
    • Press Releases
    • In the news
    • Publications
  • Contact Us

OUR PARTNERS


Copyright © 2020 CAGE Bio Inc. - All Rights Reserved.


This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept

Welcome! Check out our latest news.

CAGE Bio Announces Positive Topline Results From its Double-Blind Phase 2 Study Evaluating an Ionic Liquid formulation of 1% Tofacitinib In Patients with Atopic Dermatitis

Learn more